Publicacións en colaboración con investigadores/as de Essen University Hospital (7)

2023

  1. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

    The Lancet, Vol. 401, Núm. 10379, pp. 821-832

  2. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 7, pp. 1934-1948

  3. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2732-2747

  4. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

    Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641

2022

  1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 5, pp. 1202-1216.e23

2021

  1. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

    Chest

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1